Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nymox Pharmaceutical Corporation (NYMXF)
Nassau, BS
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.00% | +23.62% | +142.50% | +189.26% | +70.67% | +261.94% | +56.28% | -65.36% | -90.17% | -93.99% | -97.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+50.3% ★ Q4'24: +25.4% (vs Q2'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'24: +45.0% (vs Q2'23)
-
Share dilution Biotechnology: -3.4%+2.2% ★ Q4'24: +3.2% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'24: 0.00× (vs Q2'23)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Paul Averback | 16.51M | 42.30% | 15.90M | — | — | 607.0K | IN | : | 2014-02-11 | ↗ |
| 2 | 20-0975900 | 2.68M | 9.88% | — | — | — | — | OO | : | 2006-03-30 | ↗ |
| 3 | John S. Clark II | 2.68M | 9.88% | — | — | — | — | IN | : | 2006-03-30 | ↗ |
| 4 | Robert W. Butts | 2.68M | 9.88% | — | — | — | — | IN | : | 2006-03-30 | ↗ |
| 5 | Hal Pettigrew | 2.41M | 7.69% | 2.40M | 12.0K | 2.40M | — | IN | United States of America | 2010-03-31 | ↗ |
| 6 | Michael D. Starcher | 1.95M | 6.02% | 1.95M | — | 1.95M | — | IN | United States of America | 2011-02-15 | ↗ |
| 7 | Pettigrew | 1.53M | 5.19% | 732.5K | 800.5K | 732.5K | — | IN | States of America | 2008-03-14 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Patrick Doody | Vice President, General Counsel & Director | 100.0K | male |
| Lin Dodd | QA and Compliance Manager | — | female |
| Paul Averback DABP | Founder, Chairman, Chief Executive Officer & President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NYMXF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
